Life Science / Inhibitors/Agonists / / JAK

Cat. No. Name/Description Purity
A1949381 Butyzamide

98%
A1145398 Protosappanin A

98%
A315267 Gandotinib

98%
A162505 Golidocitinib

98%
A231782 Itacitinib

98+%
A639858 LFM-A13

98%
A875880 TCJL37

98%
A1364451 JAK2-IN-6

98%
A134082 WHI-P154

98%
A627263 SAR-20347

98%
A1359457 SC99

98%
A209618 AZD-1480

98+%
A124514 Oclacitinib

98%
A480267 WHI-P258

97%
A1229395 JI069

98%
A1353321 iJak-381

97%
A147657 (Z)-LFM-A13

98%
A137124 Cerdulatinib

98%
A1329297 Fedratinib hydrochloride hydrate

97%
A205043 AG490

98%

No Data

Name/Description JAK1 JAK2 JAK3 Tyk2 Other Targets Purity
Ruxolitinib +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

98%
Peficitinib 98+%
Go6976 FLT3 99%+
AZD-1480 ++++

JAK2, IC50: 0.26 nM

99%+
Fedratinib +++

JAK2, IC50: 3 nM

JAK2 (V617F), IC50: 3 nM

FLT3 99%+
WP1066 +

JAK2, IC50: 2.3 μM

98%
Curcumol 98%
AZ960 ++++

JAK2, IC50: <3 nM

JAK2, Ki: 0.45 nM

97%
GLPG0634 analog 99%+
CEP-33779 ++++

JAK2, IC50: 1.8 nM

99%+
FLLL32 +

JAK2, IC50: <5 μM

99%+
WHI-P154 +

JAK3, IC50: 1.8 μM

VEGFR,EGFR,Src 98%
ZM39923 HCl +

JAK1, pIC50: 4.4

+

JAK3, pIC50: 7.1

EGFR 97%
TG101209 +++

JAK2, IC50: 6 nM

+

JAK3, IC50: 169 nM

FLT3 99%+
Momelotinib +++

JAK1, IC50: 11 nM

++

JAK2, IC50: 18 nM

+

JAK3, IC50: 155 nM

99%+
XL019 +

JAK1, IC50: 134.3 nM

++++

JAK2, IC50: 2.2 nM

+

JAK3, IC50: 214.2 nM

FLT3 99%+
Tofacitinib +

JAK1, IC50: 112 nM

++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

98%
Tofacitinib citrate ++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

99%
FM-381 ++++

JAK3, IC50: 127 pM

99%+
Decernotinib +++

JAK1, Ki: 11 nM

JAK1, IC50: 11 nM

+++

JAK2, Ki: 13 nM

++++

JAK3, Ki: 2.5 nM

+++

TYK2, Ki: 13 nM

99%+
Cerdulatinib +++

JAK1, IC50: 12 nM

+++

JAK2, IC50: 6 nM

+++

JAK3, IC50: 8 nM

++++

TYK2, IC50: 0.5 nM

99%+
AT9283 ++++

JAK2, IC50: 1.2 nM

++++

JAK3, IC50: 1.1 nM

99%+
Ruxolitinib (S enantiomer) +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

++

TYK2, IC50: 19 nM

98%
Filgotinib +++

JAK1, IC50: 10 nM

++

JAK2, IC50: 28 nM

+

JAK3, IC50: 810 nM

+

TYK2, IC50: 116 nM

99%
Pacritinib ++

JAK2, IC50: 23 nM

JAK2 (V617F), IC50: 19 nM

+

JAK3, IC50: 520 nM

++

TYK2, IC50: 50 nM

FLT3 97%
Baricitinib +++

JAK1, IC50: 5.9 nM

+++

JAK2, IC50: 5.7 nM

++

TYK2, IC50: 53 nM

99%
Gandotinib ++

JAK1, IC50: 19.8 nM

++++

JAK2 (V617F), Ki: 0.245 nM

JAK2, IC50: 0.288 nM

++

JAK3, IC50: 48.0 nM

++

TYK2, IC50: 44 nM

FLT3 99%+
Oclacitinib maleate +++

JAK1, IC50: 10nM

++

JAK2, IC50: 18nM

+

JAK3, IC50: 99nM

+

TYK2, IC50: 84nM

98+%
NVP-BSK805 2HCl ++

JAK1, IC50: 31.63 nM

++++

JAK2, IC50: ~0.5 nM

++

JAK3, IC50: 18.68 nM

+++

TYK2, IC50: 10.76 nM

99+%
1. Hovering the mouse over the "+" can display the specific value of the relevant IC50. The more "+", the stronger the inhibitory effect. 2. "✔" Indicates that the compound has inhibitory effects on the corresponding subtypes, but there is currently no relevant data on the intensity of inhibition.